learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
5 / 801 resultslearn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Alfatradiol
a synthetic estrogen used topically as an anti-androgen
learn Triamcinolone Acetonide
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
Research
5 / 1000+ resultsresearch Melanosis Coli After Long-Term Ingestion of Cape Aloe
Long-term Cape Aloe use causes harmless colon pigmentation that can help detect polyps.
research Theoretical evaluation of interaction of some dibenzo derivatives on both androgen receptor and 5α-reductase enzyme
Certain Dibenzo derivatives may help treat prostate cancer.
research Metabolic pathways of eicosanoids—derivatives of arachidonic acid and their significance in skin
Eicosanoids are crucial for skin health, and targeting their pathways may help treat skin conditions.
research Clinical Development of Topoisomerase-Interactive Drugs
New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.
research Anthralin/dithranol in dermatology
Anthralin is effective for psoriasis and alopecia with minimal systemic side effects but can irritate the skin.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.